Logo

HOTH

Hoth Therapeutics, Inc.

HOTH

Hoth Therapeutics, Inc. • NASDAQ
$1.21 ▲ 0.83% (+0.01)
Market Cap $16.04 M
52w High $3.80
52w Low $0.66
Dividend Yield 0%
P/E -1.19
Volume 35.51K
Outstanding Shares 13.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.081M ▲ $-4.106M ▼ 0% $-0.3 ▼ $-4.106M ▼
Q2-2025 $0 $2.2M ▼ $-2.199M ▲ 0% $-0.17 ▲ $-2.199M ▼
Q1-2025 $0 $3.476M ▲ $-3.476M ▼ 0% $-0.36 ▼ $0
Q4-2024 $0 $2.383M ▲ $-2.383M ▼ 0% $-0.33 ▼ $0 ▲
Q3-2024 $0 $2.132M $-2.132M 0% $-0.31 $-2.132M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.848M ▼ $9.245M ▼ $1.013M ▲ $8.232M ▼
Q2-2025 $9.014M ▼ $10.108M ▼ $364.63K ▼ $9.743M ▼
Q1-2025 $11.317M ▲ $12.355M ▲ $815.299K ▼ $11.54M ▲
Q4-2024 $7.039M ▼ $7.713M ▼ $833.906K ▲ $6.879M ▼
Q3-2024 $8.023M $8.307M $813.033K $7.494M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.106M ▼ $-2.493M ▼ $-300K ▼ $1.627M ▲ $-1.166M ▲ $-2.493M ▼
Q2-2025 $-2.199M ▲ $-2.373M ▲ $0 $66.101K ▼ $-2.303M ▼ $-2.373M ▲
Q1-2025 $-3.476M ▼ $-2.788M ▼ $0 $7.067M ▲ $4.278M ▲ $-2.788M ▼
Q4-2024 $-2.383M ▼ $-2.028M ▼ $0 $1.061M ▲ $-983.839K ▲ $-2.028M ▼
Q3-2024 $-2.132M $-1.635M $0 $0 $-1.632M $-1.635M

Five-Year Company Overview

Income Statement

Income Statement Hoth is still a pure research-stage biotech company, so it has not generated any product revenue over the past several years. The income statement mainly reflects recurring research and operating costs, which lead to steady net losses each year. These losses look large on a per‑share basis largely because of past changes to the share count, including a reverse split, rather than because of a big change in the underlying business. This pattern is typical for an early-stage biotech that is investing in trials and development long before any potential product launches or profits.

Balance Sheet

Balance Sheet The balance sheet is very simple and quite small. Assets are limited and mostly consist of cash, with little in the way of physical assets or long-term investments. On the positive side, the company carries no debt, so there are no interest burdens or near‑term loan repayments. Equity is positive but thin, which means Hoth has only a modest financial cushion to absorb ongoing losses. Over time, progress will likely depend on the company’s ability to raise additional capital or secure partnerships to strengthen this balance sheet.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting cash being spent on research, trials, and overhead without any offsetting revenue. Free cash flow is also negative, though the company does not appear to spend much on physical equipment or facilities. This means most cash burn is tied directly to running the business and the pipeline. Given the small cash base, the sustainability of operations rests on periodic external funding or collaboration deals, and the margin for error is not very wide.

Competitive Edge

Competitive Edge Hoth occupies a narrow but potentially interesting niche in biotechnology. It focuses on conditions with clear unmet medical needs, such as skin side effects from cancer treatments, certain KIT‑driven cancers, atopic dermatitis with a bacterial component, and neuroinflammation in Alzheimer’s disease. The company tries to use regulatory shortcuts where possible and has an orphan drug designation for one cancer program, which can offer future market protections if approved. However, it is a very small player competing against much larger, well‑funded pharma and biotech firms in crowded or high‑stakes areas like oncology and Alzheimer’s. Its competitive strength rests on the uniqueness of its science and trial results rather than on scale, sales reach, or brand power.

Innovation and R&D

Innovation and R&D Innovation is the core of Hoth’s story. The pipeline spans several distinct areas: a topical drug for cancer‑therapy skin issues, an anti‑inflammatory approach to Alzheimer’s disease, a gene‑silencing treatment for KIT‑driven cancers, and a topical product targeting bacteria in atopic dermatitis. Many of these programs aim to solve problems that are not well addressed by existing therapies or that use fresh scientific angles, such as targeting neuroinflammation or silencing a mutant gene. The company also leans on collaborations, including the use of artificial intelligence with a major tech partner, to accelerate discovery and trial design. The flip side is that most of these programs are still early or mid‑stage, so scientific, regulatory, and execution risks remain high, and the breadth of the pipeline can be demanding for a small team and budget.

Summary

Overall, Hoth is a classic early‑stage biotech: no revenue, ongoing losses, a small but debt‑free balance sheet, and a business model entirely dependent on the success of its drug pipeline and its access to capital. The company’s appeal lies in its innovative, diversified set of programs aimed at underserved medical needs and in some supportive regulatory angles like orphan designation and streamlined approval pathways. At the same time, its small scale, limited financial cushion, and competition from much larger players create substantial uncertainty. The future trajectory will be driven by clinical trial readouts, regulatory milestones, partnership activity, and how effectively the company manages its cash and fundraising needs.

NEWS

November 20, 2025 · 8:13 AM UTC

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Read more

October 27, 2025 · 7:49 AM UTC

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Read more

October 21, 2025 · 8:23 AM UTC

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Read more

October 8, 2025 · 8:02 AM UTC

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Read more

October 7, 2025 · 7:57 AM UTC

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Read more